Dina Schneider

Tasso, Inc. grows in 2023 with Aptar, CardioRenal and UBC partnerships and earns MDSAP certification

Tasso, Inc. reports strong 2023 growth driven by new partnerships (Aptar Digital Health, CardioRenal, United BioSource/UBC) and rising demand for its at‑home, patient‑centric blood collection solutions, positioning the company for expanded use in decentralized clinical trials and home diagnostics. The company also earned MDSAP certification, enabling regulatory access to Australia, Canada, the U.S., and facilitating entry into markets like Brazil and Japan.